AU2013292547B2 - Dosing regimen for Janus Kinase (JAK) inhibitors - Google Patents

Dosing regimen for Janus Kinase (JAK) inhibitors Download PDF

Info

Publication number: AU2013292547B2
Authority: AU; Australia
Prior art keywords: therapeutically effective; day; dose; effective dose; jak
Prior art date: 2012-07-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

AU2013292547A

Other languages

English (en)

Other versions

AU2013292547A1 (en

Inventor

Wendy Turner COLLARD

Sallie B. COSGROVE

Andrea J. GONZALES

Phyllis B. MALPAS

Michael Rolf STEGEMANN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zoetis Services LLC

Original Assignee

Zoetis Services LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-20

Filing date

2013-07-18

Publication date

2017-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013292547(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-18 Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC

2015-01-22 Publication of AU2013292547A1 publication Critical patent/AU2013292547A1/en

2017-05-04 Application granted granted Critical

2017-05-04 Publication of AU2013292547B2 publication Critical patent/AU2013292547B2/en

2017-06-22 Assigned to ZOETIS SERVICES LLC reassignment ZOETIS SERVICES LLC Request for Assignment Assignors: ZOETIS LLC

Status Active legal-status Critical Current

2033-07-18 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Dermatology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AU2013292547A 2012-07-20 2013-07-18 Dosing regimen for Janus Kinase (JAK) inhibitors Active AU2013292547B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261674289P	2012-07-20	2012-07-20
US61/674,289		2012-07-20
US201361815803P	2013-04-25	2013-04-25
US61/815,803		2013-04-25
PCT/US2013/051015 WO2014015107A1 (en)	2012-07-20	2013-07-18	Dosing regimen for janus kinase (jak) inhibitors

Publications (2)

Publication Number	Publication Date
AU2013292547A1 AU2013292547A1 (en)	2015-01-22
AU2013292547B2 true AU2013292547B2 (en)	2017-05-04

Family

ID=48901189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2013292547A Active AU2013292547B2 (en)	2012-07-20	2013-07-18	Dosing regimen for Janus Kinase (JAK) inhibitors

Country Status (25)

Country	Link
US (1)	US9522151B2 (2)
EP (1)	EP2874630B1 (2)
JP (2)	JP6022063B2 (2)
KR (2)	KR20170034949A (2)
CN (2)	CN108354938A (2)
AU (1)	AU2013292547B2 (2)
BR (1)	BR112015000808A2 (2)
CA (1)	CA2878867C (2)
CY (1)	CY1121436T1 (2)
DK (1)	DK2874630T3 (2)
ES (1)	ES2707627T3 (2)
HK (2)	HK1209314A1 (2)
HR (1)	HRP20182088T1 (2)
HU (1)	HUE042771T2 (2)
IN (1)	IN2015DN00370A (2)
LT (1)	LT2874630T (2)
MX (1)	MX360857B (2)
NZ (1)	NZ703152A (2)
PL (1)	PL2874630T3 (2)
PT (1)	PT2874630T (2)
RS (1)	RS58242B1 (2)
SI (1)	SI2874630T1 (2)
SM (1)	SMT201900044T1 (2)
WO (1)	WO2014015107A1 (2)
ZA (1)	ZA201500134B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP201606600B (en)	2013-02-22	2017-01-10	Pfizer	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en)	2016-02-16	2021-04-13	Washington University	JAK inhibitors and uses thereof
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko)	2018-11-15	2020-12-24	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021008984A (es) *	2019-01-30	2021-09-08	Felicamed Biotechnology Co Ltd	Inhibidor jak y metodo de preparacion del mismo.
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es)	2020-12-18	2023-09-04	Boehringer Ingelheim Animal Health Usa Inc	Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
AU2022239128B2 (en) *	2021-03-16	2024-09-05	Hk Inno.N Corporation	Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
CA3216017A1 (en) *	2021-04-22	2022-10-27	Shengjian Huang	Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) *	2023-06-16	2024-12-19	The University Of Chicago	Methods and compositions for pharmaceutically relevant interactions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020019526A1 (en) *	1998-06-19	2002-02-14	Blumenkopf Todd A.	Pyrrolo[2,3-d]pyrimidine compounds
WO2010020905A1 (en) *	2008-08-20	2010-02-25	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds

2013
- 2013-07-18 CN CN201810369706.3A patent/CN108354938A/zh active Pending
- 2013-07-18 DK DK13742573.2T patent/DK2874630T3/en active
- 2013-07-18 SM SM20190044T patent/SMT201900044T1/it unknown
- 2013-07-18 SI SI201331328T patent/SI2874630T1/sl unknown
- 2013-07-18 JP JP2015523243A patent/JP6022063B2/ja active Active
- 2013-07-18 MX MX2015000871A patent/MX360857B/es active IP Right Grant
- 2013-07-18 US US14/415,047 patent/US9522151B2/en active Active
- 2013-07-18 AU AU2013292547A patent/AU2013292547B2/en active Active
- 2013-07-18 PT PT13742573T patent/PT2874630T/pt unknown
- 2013-07-18 HU HUE13742573A patent/HUE042771T2/hu unknown
- 2013-07-18 KR KR1020177007913A patent/KR20170034949A/ko not_active Ceased
- 2013-07-18 NZ NZ703152A patent/NZ703152A/en unknown
- 2013-07-18 WO PCT/US2013/051015 patent/WO2014015107A1/en not_active Ceased
- 2013-07-18 ES ES13742573T patent/ES2707627T3/es active Active
- 2013-07-18 BR BR112015000808A patent/BR112015000808A2/pt not_active Application Discontinuation
- 2013-07-18 CA CA2878867A patent/CA2878867C/en active Active
- 2013-07-18 LT LTEP13742573.2T patent/LT2874630T/lt unknown
- 2013-07-18 HK HK15109423.1A patent/HK1209314A1/xx unknown
- 2013-07-18 PL PL13742573T patent/PL2874630T3/pl unknown
- 2013-07-18 EP EP13742573.2A patent/EP2874630B1/en not_active Revoked
- 2013-07-18 CN CN201380038563.3A patent/CN104470525A/zh active Pending
- 2013-07-18 KR KR1020157001085A patent/KR20150028299A/ko not_active Ceased
- 2013-07-18 IN IN370DEN2015 patent/IN2015DN00370A/en unknown
- 2013-07-18 HR HRP20182088TT patent/HRP20182088T1/hr unknown
- 2013-07-18 RS RS20190051A patent/RS58242B1/sr unknown
2015
- 2015-01-08 ZA ZA2015/00134A patent/ZA201500134B/en unknown
2016
- 2016-08-05 JP JP2016154135A patent/JP2017019816A/ja active Pending
2018
- 2018-08-23 HK HK18110906.2A patent/HK1252083A1/zh unknown
2019
- 2019-02-14 CY CY20191100203T patent/CY1121436T1/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020019526A1 (en) *	1998-06-19	2002-02-14	Blumenkopf Todd A.	Pyrrolo[2,3-d]pyrimidine compounds
WO2010020905A1 (en) *	2008-08-20	2010-02-25	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds

Also Published As

Publication number	Publication date
CA2878867C (en)	2018-01-09
HK1209314A1 (en)	2016-04-01
MX360857B (es)	2018-11-20
HRP20182088T1 (hr)	2019-02-08
KR20170034949A (ko)	2017-03-29
ES2707627T3 (es)	2019-04-04
PL2874630T3 (pl)	2019-04-30
CY1121436T1 (el)	2020-05-29
CA2878867A1 (en)	2014-01-23
WO2014015107A1 (en)	2014-01-23
AU2013292547A1 (en)	2015-01-22
CN104470525A (zh)	2015-03-25
NZ703152A (en)	2016-03-31
BR112015000808A2 (pt)	2017-06-27
EP2874630A1 (en)	2015-05-27
EP2874630B1 (en)	2018-12-05
JP2017019816A (ja)	2017-01-26
SI2874630T1 (sl)	2019-04-30
JP6022063B2 (ja)	2016-11-09
CN108354938A (zh)	2018-08-03
SMT201900044T1 (it)	2019-02-28
US9522151B2 (en)	2016-12-20
LT2874630T (lt)	2019-02-11
HK1252083A1 (zh)	2019-05-17
MX2015000871A (es)	2015-05-07
DK2874630T3 (en)	2019-01-28
HUE042771T2 (hu)	2019-07-29
RS58242B1 (sr)	2019-03-29
US20150126535A1 (en)	2015-05-07
JP2015522620A (ja)	2015-08-06
ZA201500134B (en)	2016-08-31
PT2874630T (pt)	2019-01-31
KR20150028299A (ko)	2015-03-13
IN2015DN00370A (2)	2015-06-12

Legal Events

Date

Code

Title

Description

2017-06-22

PC1

Assignment before grant (sect. 113)

Owner name: ZOETIS SERVICES LLC

Free format text: FORMER APPLICANT(S): ZOETIS LLC

2017-08-31

FGA

Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU2013292547B2 (en)	2017-05-04	Dosing regimen for Janus Kinase (JAK) inhibitors
US11318151B2 (en)	2022-05-03	Compound pharmaceutical composition for treating skin inflammatory diseases
EP4028007B1 (en)	2025-03-26	Treatment of hidradenitis suppurativa with a jak inhibitor
US20190314382A1 (en)	2019-10-17	Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US20240390378A1 (en)	2024-11-28	Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US20240075038A1 (en)	2024-03-07	Application of pyrido[1,2-a]pyrimidinone analog
JP2024516302A (ja)	2024-04-12	結節性痒疹を治療するためのｊａｋ１経路阻害薬
US20230293544A1 (en)	2023-09-21	Methods, dosage regimens, and compositions for treating hidradenitis
US20230416244A1 (en)	2023-12-28	Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
US20190336468A1 (en)	2019-11-07	Methods and compositions for the treatment of multiple sclerosis